Christian Elze - Sep 3, 2025 Form 4 Insider Report for Protalix BioTherapeutics, Inc. (PLX)

Role
Director
Signature
/s/ Joseph R. Magnas, Attorney-in-Fact
Stock symbol
PLX
Transactions as of
Sep 3, 2025
Transactions value $
$0
Form type
4
Date filed
9/4/2025, 05:00 PM
Previous filing
Jul 3, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Elze Christian Director 2 SNUNIT STREET, SCIENCE PARK, CARMIEL, ISRAEL /s/ Joseph R. Magnas, Attorney-in-Fact 2025-09-04 0002075661

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PLX Common Stock Award +7.5K 7.5K Sep 3, 2025 By Trust F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PLX Stock Options (Right to Buy) Award $0 +15K $0.00 15K Sep 3, 2025 Common Stock 15K $1.64 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the "Plan"). The restricted shares vest in 12 equal quarterly installments commencing upon the date of grant.
F2 To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued under the Plan must be registered in the name of a trustee.
F3 The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant.